Severity of non-alcoholic steatohepatitis is associated with substitution of adipose tissue in skeletal muscle

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue 9, 2013, Pages 1507-1514

  Kitajima, Yoichiro ^a   Hyogo, Hideyuki ^b   Sumida, Yoshio ^c   Eguchi, Yuichiro ^a   Ono, Naofumi ^d   Kuwashiro, Takuya ^a   Tanaka, Kenichi ^a   Takahashi, Hirokazu ^a   Mizuta, Toshihiko ^a   Ozaki, Iwata ^a   Eguchi, Takahisa ^d   Kimura, Yuki ^a   Fujimoto, Kazuma ^a   Anzai, Keizo ^a  

^a SAGA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^d Eguchi Hospital   (Japan)

Author keywords

Lifestyle modification; Metabolic syndrome; Non alcoholic steatohepatitis

Indexed keywords

ADIPOSE TISSUE; ADULT; AGE DISTRIBUTION; ARTICLE; BIOCHEMICAL COMPOSITION; COMPUTER ASSISTED TOMOGRAPHY; CROSS-SECTIONAL STUDY; DIETARY INTAKE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; EXERCISE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTRAMUSCULAR ADIPOSE TISSUE CONTENT; JAPANESE; LIVER BIOPSY; LIVER HISTOLOGY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL SYSTEM PARAMETERS; NONALCOHOLIC FATTY LIVER; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SKELETAL MUSCLE;

LIFESTYLE MODIFICATION; METABOLIC SYNDROME; NON-ALCOHOLIC STEATOHEPATITIS;

ADULT; AGED; BIOPSY; CROSS-SECTIONAL STUDIES; FATTY LIVER; FEMALE; HUMANS; INTRA-ABDOMINAL FAT; LIFE STYLE; LIVER; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MUSCLE, SKELETAL; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84897621299     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12227     Document Type: Article

References (47)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
2. The International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. 2006 Cited 1 March 2013. Available from URL: http://www.idf.org/webdata/docs/IDF_metasyndrome_definition.pdf
3. Kissebah AH, Vydelingum N, Murray R etal. Relation of body fat distribution to metabolic complications of obesity. J. Clin. Endocrinol. Metab. 1982; 54: 254-260.
4. Fujioka S, Matsuzawa Y, Tokunaga K, Tarui S. Contribution of intraabdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism 1987; 36: 54-59.
5. Matsuzawa Y, Shimomura I, Nakamura T, Keno Y, Kotani K, Tokunaga K. Pathophysiology and pathogenesis of visceral fat obesity. Ann. N. Y. Acad. Sci. 1993; 676: 270-278.
6. Eguchi Y, Eguchi T, Mizuta T etal. Visceral fat accumulation and insulin resistance are important factors in nonalcoholic fatty liver disease. J. Gastroenterol. 2006; 41: 462-469.
7. Ishibashi E, Eguchi Y, Eguchi T etal. Waist circumference correlates with hepatic fat accumulation in male Japanese patients with non-alcoholic fatty liver disease, but not in females. J. Gastroenterol. Hepatol. 2008; 23: 908-913.
8. Eguchi Y, Mizuta T, Ishibashi E etal. Hepatitis C virus infection enhances insulin resistance induced by visceral fat accumulation. Liver Int. 2009; 29: 213-220.
9. Oza N, Eguchi Y, Mizuta T etal. A pilot trial of body weight reduction for nonalcoholic fatty liver disease with a home-based lifestyle modification intervention delivered in collaboration with interdisciplinary medical staff. J. Gastroenterol. 2009; 44: 1203-1208.
10. Kitajima Y, Eguchi Y, Ishibashi E etal. Age-related fat deposition in multifidus muscle could be a marker for nonalcoholic fatty liver disease. J. Gastroenterol. 2010; 45: 218-224.
11. Cusi K. Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis. Clin. Liver Dis. 2009; 13: 545-563.
12. Byrne CD. Dorothy Hodgkin Lecture 2012: non-alcoholic fatty liver disease, insulin resistance and ectopic fat: a new problem in diabetes management. Diabet. Med. 2012; 29: 1098-1107.
13. Graner M, Siren R, Nyman K etal. Cardiac steatosis associates with visceral obesity in nondiabetic obese men. J. Clin. Endocrinol. Metab. 2013; 98: 1189-1197.
14. Goodpaster BH, Thaete FZ, Simoneau JA, Kelley DE. Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat. Diabetes 1997; 46: 1579-1585.
15. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006; 444: 881-887.
16. Torres DM, Harrison SA. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology 2008; 134: 1682-1698.
17. Haffner SM, Kennedy E, Gonzalez C, Stern MP, Miettinen H. A prospective analysis of the HOMA model. The Mexico City Diabetes Study. Diabetes Care 1996; 19: 1138-1141.
18. Katz A, Nambi SS, Mather K etal. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J. Clin. Endocrinol. Metab. 2000; 85: 2402-2410.
19. Sumida Y, Yoneda M, Hyogo H etal. Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterol. 2012; 12: 2.
20. Sterling RK, Lissen E, Clumeck N etal. APRICOT Clinical Investigators: development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317-1325.
21. Sumida Y, Yoneda M, Hyogo H etal. A simple clinical scoring system using ferritin, fasting insulin and type IV collagen 7s for predicting steatohepatitis in nonalcoholic fatty liver disease. J. Gastroenterol. 2011; 46: 257-268.
22. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver diseases: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-1419.
23. Rafiq N, Bai C, Fang Y etal. Long-term follow-up of patients with nonalcoholic fatty liver. Clin. Gastroenterol. Hepatol. 2009; 7: 234-238.
24. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Non-alcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am. J. Gastroenterol. 1999; 94: 2467-2474.
25. Kleiner DE, Brunt EM, Van Natta M etal. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321.
26. Saadeh S, Younossi ZM, Remer EM etal. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 745-750.
27. Piekarski J, Goldberg HI, Royal SA, Axel L, Moss AA. Difference between liver and spleen CT number in the normal adult: its usefulness in predicting the presence of diffuse liver disease. Radiology 1980; 137: 727-729.
28. Yoshizumi T, Nakamura T, Yamane M etal. Abdominal fat: standardized technique for measurement at CT. Radiology 1999; 211: 283-286.
29. Examination Committee of Criteria for "Obesity Disease" in Japan, Japan Society for the Study of Obesity. New criteria for "obesity disease" in Japan. Circ. J. 2002; 66: 987-992.
30. Krotkiewski M, Bjorntorp P. Muscle tissue in obesity with different distribution of adipose tissue. Effects of physical training. Int. J. Obes. 1986; 10: 331-341.
31. Oberbach A, Bossenz Y, Lehmann S etal. Altered fiber distribution and fiber-specific glycolytic and oxidative enzyme activity in skeletal muscle of patients with type 2 diabetes. Diabetes Care 2006; 29: 895-900.
32. Kawaguchi T, Shiba N, Takano Y etal. Hybrid training of voluntary and electrical muscle contractions decreased fasting blood glucose and serum interleukin-6 levels in elderly people: a pilot study. Appl. Physiol. Nutr. Metab. 2011; 36: 276-283.
33. Sinha R, Dufour S, Petersen KF etal. Assessment of skeletal muscle triglyceride content by (1) H nuclear magnetic resonance spectroscopy in lean and obese adolescents: relationships to insulin sensitivity, total body fat, and central adiposity. Diabetes 2002; 51: 1022-1027.
34. Tamura Y, Tanaka Y, Sato F etal. Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients. J. Clin. Endocrinol. Metab. 2005; 90: 3191-3196.
35. Thomas EL, Brynes AE, Hamilton G etal. Effect of nutritional counselling on hepatic, muscle and adipose tissue fat content and distribution in non-alcoholic fatty liver disease. World J. Gastroenterol. 2006; 12: 5813-5819.
36. Johnson NA, Sachinwalla T, Walton DW etal. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology 2009; 50: 1105-1112.
37. Kim D, Choi SY, Park EH etal. Nonalcoholic fatty liver disease is associated with coronary artery calcification. Hepatology 2012; 56: 605-613.
38. Visser M, Kritchevsky SB, Goodpaster BH etal. Leg muscle mass and composition in relation to lower extremity performance in men and women aged 70 to 79: the health, aging and body composition study. J. Am. Geriatr. Soc. 2002; 50: 897-904.
39. Goodpaster BH, Theriault R, Watkins SC, Kelley DE. Intramuscular lipid content is increased in obesity and decreased by weight loss. Metabolism 2000; 49: 467-472.
40. She P, Reid TM, Bronson SK etal. Disruption of BCATm in mice leads to increased energy expenditure associated with the activation of a futile protein turnover cycle. Cell Metab. 2007; 6: 181-194.
41. Zhang Y, Guo K, LeBlanc RE, Loh D, Schwartz GJ, Yu YH. Increasing dietary leucine intake reduces diet-induced obesity and improves glucose and cholesterol metabolism in mice via multimechanisms. Diabetes 2007; 56: 1647-1654.
42. Holland-Fischer P, Andersen PH, Lund S etal. Muscle GLUT4 in cirrhosis. J. Hepatol. 2007; 47: 212-219.
43. Pedersen BK, Febbraio MA. Muscle-derived interleukin-6-a possible link between skeletal muscle, adipose tissue, liver, and brain. Brain Behav. Immun. 2005; 19: 371-376.
44. Pedersen BK, Febbraio MA. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol. Rev. 2005; 88: 1379-1406.
45. Lee YM, Sutedja DS, Wai CT etal. A randomized controlled pilot study of Pentoxifylline in patients with non-alcoholic steatohepatitis (NASH). Hepatol. Int. 2008; 2: 196-201.
46. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286: 327-334.
47. Awazawa M, Ueki K, Inabe K etal. Adiponectin enhances insulin sensitivity by increasing hepatic IRS-2 expression via a macrophage-derived IL-6-dependent pathway. Cell Metab. 2011; 13: 401-412.